LIVE WEBINAR: Thursday, January 21 2021, 5:00 PM – 6:00 PM Eastern Time

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Chronic Lymphocytic Leukemia

Join us on Thursday, January 21st for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Matthew S Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts


Jennifer Woyach, MD
Professor
Section Head, CLL and Hairy Cell Leukemia
Associate Division Director for Clinical Research
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Thursday, January 21, 2021
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

MODULE 1: Optimal Management of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL)

  • Key biologic factors in the selection of initial therapy for patients with CLL requiring active treatment (eg, IGHV mutation status, del(17p)/TP53 status, bulk of disease)
  • Patient-related factors in front-line decision-making, such as hypertension, chronic kidney disease, need for anticoagulation, compliance concerns and treatment for gastroesophageal reflux disease
  • Available efficacy and safety findings with Bruton tyrosine kinase (BTK) inhibitors alone or in combination with an anti-CD20 antibody for patients with treatment-naïve CLL
  • Optimal incorporation of BTK inhibitors into first-line management algorithms; current role in combination with anti-CD20 antibodies
  • Spectrum, frequency and severity of toxicities associated with various BTK inhibitors; optimal management strategies and implications for treatment selection and discontinuation
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III CLL14 trial evaluating venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with treatment-naïve CLL
  • Rates and sustainability of minimal residual disease (MRD) negativity with venetoclax/obinutuzumab
  • Optimal integration of venetoclax/obinutuzumab into front-line treatment algorithms
  • Current and potential role of MRD assessment in CLL management

MODULE 2: Treatment Options for Patients with Relapsed/Refractory (R/R) CLL; Future Directions in CLL Management

  • Key efficacy and safety findings from the Phase III ASCEND trial comparing acalabrutinib to rituximab, each in combination with either idelalisib or bendamustine, for patients with R/R CLL; current role of BTK inhibitors in this setting
  • Long-term outcomes from the Phase III MURANO trial evaluating venetoclax/rituximab versus bendamustine/rituximab for patients with R/R CLL; practical application of venetoclax in the R/R setting
  • Available data with and current clinical roles of the PI3K inhibitors idelalisib and duvelisib in the CLL treatment paradigm
  • Incidence and optimal management of Richter’s transformation
  • Biologic rationale for and early efficacy and safety data with the CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel in the Phase I/II TRANSCEND CLL 004 study for patients with R/R CLL
  • Mechanistic rationale for combining BTK inhibitors with Bcl-2 inhibitors and/or anti-CD20 antibodies in the management of CLL
  • Available efficacy and safety outcomes from studies evaluating novel combinations of BTK inhibitors with Bcl-2 inhibitors and/or anti-CD20 antibodies for previously untreated and R/R CLL; ongoing Phase III studies
  • Other promising agents and strategies under investigation for CLL

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Individualize the selection of systemic therapy for patients with newly diagnosed chronic lymphocytic leukemia (CLL), considering clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to discern how this strategy can be optimally integrated into nonresearch treatment.
  • Appraise the Phase III data supporting the recent FDA approval of acalabrutinib for newly diagnosed or previously treated CLL, and identify patients for whom treatment with this agent may be appropriate.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how to appropriately integrate this regimen into current treatment decision-making.
  • Analyze how patient age, performance status, prior therapeutic exposure and biologic and disease-related factors affect the selection and sequencing of therapy for relapsed/refractory (R/R) CLL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies employed in the management of CLL.
  • Develop an understanding of the biologic rationale for the use of chimeric antigen receptor T-cell therapy for patients with R/R CLL, appreciate available efficacy and safety data and consider the potential role of this novel therapeutic approach in practice.
  • Recall available and emerging data with other investigational agents, combinations and strategies currently under investigation for CLL, and where applicable, refer eligible patients for trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr DavidsAdvisory Committee: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc. Dr WoyachAdvisory Committee: AbbVie Inc, ArQule Inc, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.